Schizophrenia DisordersNCT06911723
Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy Controls
A study testing Brief Activities in people with Schizophrenia Disorders, run by University of Alabama at Birmingham at 1 site in United States.
Trial summary
This is a study investigating how brief online activities can influence mood and attitudes. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Schizophrenia Disorders
- What is being tested?
- Brief Activities
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Aug 2025to Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- aged 18-65
- schizophrenia group - have a psychotic disorder diagnosis
- healthy control group - Do not have a current DSM-5 diagnosis via the SCID-5
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Alabama at Birmingham
Birmingham, Alabama, 35223-1517
Lauren Luther, PhD, 205-530-1117, cas-treatlab@uab.edu
About this study
This is a study investigating how brief online activities can influence mood and attitudes.
- Conditions
- Schizophrenia Disorders
- Being tested
- Brief Activities
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Brief ActivitiesBehavioural
The activities will be completed online.
| Study group | Role | What they receive |
|---|---|---|
| Emotion Coping Activities | Experimental | Not described Receives: Behavioral: Brief Activities |
| Belief Modifying Activities | Experimental | Not described Receives: Behavioral: Brief Activities |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Health Questionnaire - PHQ-9
Depression measure
Measured: Assessed at baseline (day 1) and after study completion, an average of a week
Generalized Anxiety Disorder 7-item - GAD-7
Anxiety measure
Measured: Assessed at baseline (day 1) and after study completion, an average of a week
The Motivation and Pleasure Scale-Self-Report - MAP-SR
Negative symptoms
Measured: Assessed at baseline (day 1) and after study completion, an average of a week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2025
- Study start20 Aug 2025
- Primary completionOct 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Schizophrenia DisordersStudies of the same condition, open and under way.
- More trials run by University of Alabama at BirminghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lauren Luther, University of Alabama at Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06911723
- Sponsor's protocol ID
- IRB-300014130
- Other IDs
- Internal Award
- Status last verified
- Aug 2026
- First submitted
- 18 Mar 2025
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Upon reasonable request, we will share data.
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy Controls
- ClinicalTrials.gov ID
- NCT06911723
- Acronym / sponsor ID
- IRB-300014130
- Conditions
- Schizophrenia Disorders
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of Alabama at BirminghamUniversity, hospital or other
- Study start
- 20 Aug 2025 (actual)
- Primary completion
- Oct 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 4 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study investigating how brief online activities can influence mood and attitudes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Emotion Coping Activities | Experimental | Behavioral: Brief Activities |
| Belief Modifying Activities | Experimental | Behavioral: Brief Activities |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- aged 18-65
- schizophrenia group - have a psychotic disorder diagnosis
- healthy control group - Do not have a current DSM-5 diagnosis via the SCID-5
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Brief ActivitiesThe activities will be completed online. | Behavioural | Belief Modifying Activities, Emotion Coping Activities |
Primary outcome
Patient Health Questionnaire - PHQ-9
Time frame: Assessed at baseline (day 1) and after study completion, an average of a week
Depression measure
Generalized Anxiety Disorder 7-item - GAD-7
Time frame: Assessed at baseline (day 1) and after study completion, an average of a week
Anxiety measure
The Motivation and Pleasure Scale-Self-Report - MAP-SR
Time frame: Assessed at baseline (day 1) and after study completion, an average of a week
Negative symptoms
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
- Individual participant dataSharing planned: Undecided. Upon reasonable request, we will share data.
Related trials for Schizophrenia Disorders
Recruiting
Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
Psychotic Disorders, Family Members
RecruitingObservational study
The ATP Project (Antipsychotic-TEP-Psychosis)
First Episose Psychosis, Metabolic Disease
RecruitingPhase 2
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Schizophrenia
Recruiting
Interest of the Tool: Evaluation of Specific Care in an Ecological Environment for Patients Suffering From Schizophrenia-like Disorders
Patients With Schizophrenia-like Disorders
RecruitingPhase 2
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Schizophrenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Brief Activities in people with Schizophrenia Disorders, run by University of Alabama at Birmingham at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lauren Luther, PhD ((205) 934-3850, cas-treatlab@uab.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Health Questionnaire - PHQ-9 (time frame: Assessed at baseline (day 1) and after study completion, an average of a week). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.